Debiopharm and Cenix Partner on Preclinical Services

Related tags Cancer

Debiopharm and Cenix Partner on Preclinical Services
Debiopharm says Cenix’ RNAi screening technology was the key reason in selecting the CRO for its drug development services.

Preclinical contract research firm Cenix BioScience has signed a research agreement with Swiss-based biopharma company Debiopharm to support ongoing efforts to develop novel therapeutic drug candidates by identifying predictive biomarkers.

“Cenix offers a unique cell high throughput RNAi screening technology, as a CRO”​ said Debiopharm spokesperson Béatrice Hirt to

Using the Definiens XD image analysis platform, Cenix will establish multi-parametric microscopy-based readouts in a range of human cancer cell models to identify genes and pathways that either enhance or suppress the drug’s therapeutic effects.

In a press release, Cenix’s CEO/CSO Dr. Christophe Echeverri said: “We are very excited to launch this new relationship with Debiopharm, extending their repertoire with what we consider to be some of the most strategically powerful cell-based screening paradigms developed to date.”

When asked, Debiopharm declined to give financial details of the collaboration.

Related topics Preclinical Research Preclinical

Related news

Related products

show more

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us


View more